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Abstract 
 
The rapid development of different imaging modalities related to radiation therapy (RT) 
has largely affected the entire RT process from the planning phase of the treatment to the 
final treatment delivery. Treatment planning requires accurate anatomical information 
that can be provided by computed tomography (CT) and magnetic resonance imaging 
(MRI). Additional functional information about tissues and organs can be obtained by 
functional MRI or nuclear medicine imaging techniques such as single-photon emission 
tomography or positron emission tomography. The introduction of cone-beam computed 
tomography (CBCT) imaging to the RT delivery process has also opened new 
possibilities for RT treatment. In the past, mainly bony anatomy was visualized with 
planar imaging, which was used for the localization of the treatment. With CBCT also the 
prevailing soft tissue anatomy in addition to bones can be verified on a daily basis. By 
taking advantage of the growing amount of information obtainable by imaging, RT 
treatment plans can be customized further to suit the individual anatomical and 
physiological properties of patients.  
 
The focus of this thesis is on advanced methods for taking the individual variation in 
patients’ physiology into account during the RT treatment planning. Two particular cases 
of variation are investigated: bladder filling and deformation during the RT of urinary 
bladder cancer, and radiation-induced changes of salivary gland function related to the 
RT of head and neck cancer. In both cases, pre-treatment imaging is used to create a 
patient-specific model to estimate the changes that would take place during the RT. The 
aim is to take these predicted changes into account in the treatment planning process, with 
the goal of protecting normal tissues. 
 
At Helsinki University Central Hospital (HUCH), a method of adaptive radiation therapy 
(ART) was designed and clinically implemented for the treatment of urinary bladder 
cancer. In the applied workflow, four consecutive CT scans for RT treatment planning 
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were used to capture the changes in bladder shape and size while the bladder was filling. 
Assuming that a similar bladder filling pattern applies during the course of RT, four 
treatment plans corresponding to the different bladder volumes were prepared and stored 
in a plan library. Before each treatment fraction a CBCT scan was performed. The 
treatment plan, which was the closest match to the bladder shape and size of the day, was 
selected from the library and delivered accordingly. The use of ART enabled better 
conformity of the treatment. It considerably reduced the absorbed dose to the intestinal 
cavity, as compared to the non-adaptive approach. Furthermore, the dose coverage in the 
urinary bladder was not compromised, while the treatment margins were substantially 
reduced. Overall, the method was found to be feasible, and it was rapidly taken into 
clinical practice.  
 
A model for predicting post-RT salivary flow was constructed and evaluated for the 
treatment of head and neck cancer. The model was based on pre-RT quantitative 99mTc-
pertechnetate scintigraphy, direct measurement of total salivary flow and population-
based dose-response behaviour. A good correlation was found between the modelled and 
the measured values of saliva flow rate. Hence, the model can be used as a predictive tool 
for risk-adapted treatment planning. One possible explanation for the remaining 
discrepancies between the predicted and the measured saliva flow rate values may be 
patients’ individual responses to radiation. 
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1 Introduction 
 
 
1.1  The role of medical imaging in the individualization of RT process 
 
Traditionally, the external beam radiation therapy (RT) process has been seen as a fairly 
rigid and predictable chain of standard procedures. This process consists of  
1) medical imaging with a carefully fixed patient position, providing three-
dimensional (3D) anatomical information of the target volume, organs at risk 
(OARs) and surrounding tissues,  
2) treatment planning including segmentation of the volumes of interest in the 
treatment planning images, selection of the RT technique, planning of treatment 
field set-up and calculation of the corresponding radiation dose distribution and  
3) treatment delivery typically carried out with a linear accelerator (linac) in a series 
of successive treatment fractions. 
 
During the last decades, medical imaging has vastly increased its importance in the 
process of RT treatment planning and delivery. Computed tomography (CT), magnetic 
resonance (MR) or nuclear medicine (NM) imaging can be applied to characterize the 
individual patient anatomy and physiology [1]. CT and MR imaging are used to obtain 
3D anatomical information for the RT workflow. Functional MR and NM imaging, 
including positron emission tomography (PET), single-photon emission computed 
tomography (SPECT) and planar scintigraphy, can provide additional functional 
information of the target volume and normal tissues to be used in treatment planning. 
Dose calculations are usually based on the anatomy and heterogeneous tissue electron 
density information of a CT image [1]. In the treatment delivery, imaging is applied for 
ensuring the proper localization of the RT treatment. Modern linacs are equipped with an 
integrated X-ray imaging device, which can be utilized either for two-dimensional (2D) 
planar imaging or 3D cone-beam computed tomography (CBCT). The 2D imaging 
superimposes underlying anatomical structures of medical interest. Therefore, quite often 
mainly the bony anatomy can be visualized, and the patient position and localization of 
the treatment is verified and corrected based on the bones. In contrast, the other on-board 
solution, 3D CBCT, overcomes this technical aspect. In addition to bony structures, 
CBCT is able to visualize soft tissue anatomy. This is a major advantage when treating 
soft tissue tumours, such as pelvic tumours. Volumetric data can be used to detect changes 
and deformation in tissues and organs during the course of RT, thus sometimes revealing 
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for example the need for the re-planning of the treatment. 
 
As anatomical and physiological features may vary substantially between individual 
patients, the RT is planned using population-based knowledge of the properties of an 
average patient. The basis of this knowledge lies in the mixture of previous research 
reported in the literature and the clinical experience gained at the department. Treatment 
planning is based on the individual anatomical information captured at the instant of 
planning CT imaging. However, many assumptions and generalizations are usually made 
about the geometry and dynamics of a volume to be treated, the effectiveness of treatment 
and the probability of radiation-induced side-effects. Anatomical variations, including 
organ motion and deformation of both tumour and normal tissues, complicate RT 
treatment. The treated volume should be large enough to accommodate most variations 
seen in individual patients, but on the other hand it should be as small as possible to 
minimize treatment toxicity. The historical approach is to measure the variations for a 
certain treatment site in a large population, and calculate how much the treated volume 
needs to be expanded beyond the tumour to be able to cover most variations. Several 
techniques for deriving a suitable safety margin have been reported in the literature [2-6]. 
A safety margin may be designed based on the probability of the correct target dosage, 
for example to ensure a 95% minimum dose in target volume for 90% of patients [4]. A 
corresponding standard treatment margin is then applied for all patients regardless of 
whether they show large variations or not. A similar convention applies for the definition 
of the prescribed doses. The goal is to give the dose enabling maximum probability of 
cure without complications, which is once again defined in a population. However, in 
reality, a patient may crucially differ from the average patient, thus introducing 
uncertainty in the treatment delivery and the prediction of the treatment outcome.  
 
The growing selection of different imaging techniques provide important tools for 
customizing treatments to the needs of an individual patient. More accurate, patient-
specific anatomical and physiological information may help reducing the overall 
uncertainty in the RT process. This may enable dose escalation in the tumour and/or 
reduce treatment toxicity by improved shielding of the OARs. 
 
1.2 Adaptive RT 
 
In adaptive radiation therapy (ART) the traditional chain of events along the RT process 
is usually broken to achieve highly individualized treatment. The concept was introduced 
in the literature by Di Yan et al. [7]. Their article defined ART as a closed loop of the RT 
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process, where systematic feedback of the individual patient variations is used to modify 
the treatment plan. During the process variations are systematically monitored and 
incorporated via re-optimization of the treatment plan [7]. This method provides a 
possibility to tailor treatment margins to specific patients and/or alter treatment doses to 
enable safe dose escalation. 
 
Soft tissue tumours in the pelvic area are particularly suitable for ART, as the pelvic 
region is subject to continuous changes driven by physiological activity [8]. Bowel 
movement and rectal and bladder filling cause organ motion and deformations in the 
pelvic region [9]. Thus, the prostate, urinary bladder, rectum and cervix are mobile targets 
for RT, and organ deformation can be a major problem for these tumour sites [10-15]. 
Hence, it is not surprising that many of the first clinical implementations of ART 
techniques were particularly reported for pelvic tumours [8,16-18]. 
 
Fundamentally, there are three different scenarios for applying treatment plan 
modifications. In the first approach, the treatment plan can be altered off-line, based on a 
pre-defined triggering criteria or at a certain temporal point during the treatment course 
(offline ART) [16,18-23]. In this scenario, anatomic variations can be observed and 
measured during the initial treatment fractions using e.g. CBCT imaging. This 
information may then be used to construct a new target volume for re-planning the 
treatment, or if large deformations were detected, it could trigger a new treatment 
planning CT. In the offline ART method, the original treatment plan is replaced by a new, 
modified treatment plan, which aims at incorporating the anatomical variations seen 
during the previous treatment fractions. The other two approaches aim at quantifying the 
individual variations before each treatment fraction, and immediately adapting the 
treatment to the current anatomy (online ART). In the second adaptive method, several 
alternative treatment plans are prepared and stored in a so-called plan library [24-26]. The 
decision of the treatment plan selection is made on-line on a daily basis. Usually based 
on pre-treatment CBCT imaging, the anatomy of interest is determined each day, and the 
treatment plan that has the best correspondence to the current anatomy is selected. The 
third option is to modify the treatment plan on-line by either full re-optimization of the 
dose distribution or e.g. beam aperture modification. In this approach, usually volumetric 
imaging is used to define the anatomic situation before the treatment, and immediate 
actions are taken, while the patient lies on the treatment table, to adjust the original 
treatment plan to fit the current anatomy. The challenge of the on-line re-optimization 
method is that it requires a smooth and a rapid workflow including a reliable deformable 
registration and fast re-optimization and dose accumulation. It also requires special 
expertise of the personnel responsible for treatment delivery. Hence, this method is not 
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easily introduced into a clinical routine, although a pioneering clinical implementation in 
MRI-based on-line re-optimization was introduced very recently [27]. 
 
ART for urinary bladder cancer 
 
In 2014, urinary bladder cancer was the fourth common cancer in men, representing 5.7% 
of all male cancers in Finland, being more common in male than in female population 
(appearance of 15.4 vs 3.7/100.000) [28]. Urinary bladder is a hollow organ consisting of 
epithelium, connective tissue and several muscular layers [29]. The choice of the cancer 
treatment is dependent on whether the tumour has invaded into the muscular layers in the 
bladder wall or continues to spread to adjacent organs [29,30]. In Finland, the standard 
treatment for localized muscle-invasive bladder carcinoma is a surgical resection of the 
whole bladder (radical cystectomy). However, an alternative treatment enabling organ 
preservation is RT, which is often preceded by transurethral resection of the bladder 
tumour and combined with chemotherapy [29,31,32]. This option may be offered for 
patients with inoperable tumours or who are unfit for cystectomy (e.g. elderly patients). 
Urinary bladder is a challenging target for RT. The filling of the bladder varies, hence 
affecting the treatment volume. In addition, there are daily variations of shape and 
position of the bladder caused by rectal filling or bowel loops adjacent to the bladder. 
Previously, this problem has been solved by adding large treatment margins, usually 
within the range of 15-20 mm, around the bladder [33-36], consequently resulting in large 
irradiated volumes of normal tissue. 
 
In RT of urinary bladder cancer, the first ART applications involved controlled offline 
re-planning. In a study reported in 1993 [37], which can be considered as an early clinical 
application of a very simple bladder ART workflow, all patients had a second CT scan 
half way through their treatment. The changes in the target volume and adequacy of the 
original treatment plan were assessed, and a new treatment plan was created if found 
necessary. The following contributions to the literature in clinically applied bladder ART 
introduced more sophisticated ART workflows. The first studies addressed offline ART 
strategies [18,20], while later a shift towards the online ART approaches was seen.  
 
At present, the dominating ART strategy for bladder cancer is based on the use of pre-
calculated treatment plan libraries. To quantify variations in bladder shape, size and 
position for generating the plan library, mainly two approaches have been applied. The 
first method, which is presented in this thesis and currently used at Helsinki University 
Central Hospital (HUCH), aims at capturing different bladder volumes from an empty to 
a full bladder by multiple successive planning CT scans. An individual treatment plan is 
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calculated for each filling state of the bladder and stored in a plan library. This kind of 
method can also be based on merely two CT acquisitions, one with an empty and another 
with a full bladder, by using interpolation tools or varying margin expansions [25,38,39]. 
The idea behind this method is to provide a solution for varying bladder filling, while also 
allowing some bladder deformation. In the second approach, the treatment is initiated as 
a conventional RT, and deformation and positional changes of an empty bladder are 
monitored using the CBCT images acquired during the first treatment fractions [24,40]. 
Here, the variations in the shape and position of the empty bladder are incorporated by 
combining the information from daily CBCTs into the adaptive target volumes. Based on 
these volumes, a treatment plan library is created and applied for the remaining treatment 
fractions. Another method suggested for plan library creation is expanding the bladder 
volume in a single treatment planning CT by several different margins [35,41]. However, 
this technique does not provide any information on the individual, patient-specific 
patterns of bladder expansion.  
 
The different clinically implemented plan-library-based ART workflows for bladder 
cancer are listed in Table 1-1, following the chronological order of appearance in the 
literature. Simulation studies of online re-optimization for bladder ART have been 
performed [42,43], but so far no clinical implementations have been reported. 
 
A large part of this thesis concentrates on accounting for the changes in the urinary 
bladder during the treatment course. The plan-library-based protocol for urinary bladder 
ART implemented at HUCH will be presented and evaluated. The suggested workflow 
will also be compared to another plan-library-based ART protocol that has been clinically 
applied in Aarhus University Hospital (AUH), Denmark [40]. 
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Table 1-1. The different clinically implemented plan-library-based ART workflows for bladder 
cancer introduced in the literature. 
 
Study Site Treatment plan library 
Foroudi et al, 
2011, [24] 
Peter MacCallum Cancer 
Centre, Melbourne 
Three plans created from a composite 
of one planning CT and five CBCTs 
Murthy et al, 
2011, [41] 
Tata Memorial Centre, 
Mumbai 
Six plans created from planning CT 
by varying CTV-to-PTV margin 
Tuomikoski et al, 
2011, [Study I] 
Helsinki University Central 
Hospital, Helsinki 
Four plans created from four planning 
CTs 
Meijer et al, 
2012, [25] 
Catharina Hospital Eindhoven, 
Eindhoven 
Six plans created from two planning 
CTs by using inter- and extrapolation 
McDonald et al, 
2013, [38] 
The Royal Marsden Hospital, 
Sutton 
Three plans created from two 
planning CTs by varying CTV-to-
PTV margin 
Vestergaard et al, 
2014, [40] 
Aarhus University Hospital, 
Aarhus and Copenhagen 
University Hospital, Herlev 
Three plans created from a composite 
of one planning CT and four CBCTs 
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1.3 Risk-adapted RT 
 
In addition to anatomic variations, ART can be applied to compensate for the radiation 
sensitivity of normal tissues or tumour. The latter option was also implied by Yan et al: 
“the concept of ART can also be applied to compensate for other treatment variations 
such as radiation sensitivity and density of clonogenic cells when they become 
measurable during the treatment course” [7]. There are a few examples of risk-adaptive 
RT in the literature. To meet the criteria for the definition of ART, some indicator of the 
radiation sensitivity of tissues of interest should be measured during the course of RT and 
trigger treatment plan adaptation. There are many examples of procedures applied for 
determining tumour response or normal tissue function during RT using functional 
imaging [44,45]. Some of these methods have been suggested as predictive tools for 
treatment outcome [46-48], and they could even be used as a basis for individualized 
treatment plan modifications [49-54]. The intended modifications aim at dose escalation 
to a radioresistant tumour or parts of the tumour, boosting a shrinking tumour or sparing 
normal tissues. However, adapting treatment to the individual biology of the tumour or 
normal tissues may be problematic due to different uncertainties related to functional 
imaging [55,56]. 
 
One possibility of adapting RT based on the potential risks caused to the patient is the use 
of different predictive models as a tool for treatment planning. In this case, the risk of 
producing a certain side-effect for the given treatment is evaluated, and the treatment plan 
or the prescribed dose can be adjusted based on this risk evaluation [49,52,57,58]. Here, 
the risk evaluation and the required treatment modifications usually take place before the 
initiation of RT treatment. 
 
One example of the modelling of radiation-induced normal tissue effects is the prediction 
of salivary gland function related to RT of head and neck cancers. These models require 
the use of pre-treatment functional measurement to determine the initial activity of the 
salivary glands. Several methods have been reported in the attempt of quantifying salivary 
gland function for this purpose. The applied techniques include direct measurements of 
secreted saliva volume, functional MRI, PET, SPECT and scintigraphy [59-65].  
 
The latter part of this thesis addresses the prediction of post-RT salivary gland function. 
A predictive model, to be later used for risk-adapted treatment planning for RT of head 
and neck cancers, is introduced and evaluated.
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2 Aims of the thesis 
 
 
This thesis aimed to establish clinically feasible methods of predicting physiology-driven 
changes on the individual patient level, and to incorporate these changes into RT 
treatment planning. Patients with two different types of cancer were involved in this 
study: urinary bladder cancer and head and neck cancers. In both patient populations 
methods of responding to the individual physiology were developed with the goal of 
reducing the absorbed dose to the normal tissues.  
 
The specific aims were: 
 
1. to quantify changes in the shape and size of the urinary bladder taking place during 
and between RT treatment fractions (Studies I and II), 
 
2. to design and clinically implement a workflow for ART of urinary bladder cancer, 
to compare this workflow with the conventional, non-adaptive approach, and also 
with another clinically used ART workflow (Studies I and III), and 
 
3. to quantify and predict RT-induced changes in salivary gland function, and to 
assess inter-patient differences in post-RT salivary gland function (Study IV).  
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3 Materials and methods 
 
 
3.1 Modeling of organ motion/physiological changes for ART of urinary 
bladder cancer 
 
At HUCH, an ART strategy for urinary bladder cancer was designed and clinically 
implemented in 2009. The motivation behind the new treatment technique was to reduce 
the treatment margins in order to minimize the irradiated normal tissue volume that could 
potentially affect treatment toxicity. The ART protocol at HUCH has evolved over the 
years, hence the current workflow is described in the following. 
 
3.1.1 The workflow for online-ART of urinary bladder cancer at HUCH 
 
In the HUCH protocol, the prediction of changes in bladder volume and shape is based 
on repeated planning CT imaging. The different states of bladder filling are captured by 
a sequence of four repeated CT scans acquired at 15-minute intervals. Right before the 
first scan (t=0) the patients empty their bladders and drink 8 dl of water. For all four CTs 
with different bladder volumes a set of contours is generated including clinical target 
volumes (CTV), planning target volumes (PTV), bladder (if not equal to CTV), rectum 
and intestinal cavity (IC). These structures are copied into the first planning CT with an 
empty bladder, which is used for treatment plan calculations. A library of four treatment 
plans, one plan for each PTV, is generated using volumetric-modulated arc therapy 
(VMAT) or intensity-modulated radiation therapy (IMRT). Sometimes bladder filling 
during the planning CT sequence is found to be modest, and then individual decisions of 
excluding one or even two of the treatment plans for the middle-sized PTVs can be made. 
 
On each day of treatment, patients empty their bladder before being positioned on the 
treatment couch, and a daily CBCT image is acquired. A soft tissue match is used between 
the CBCT and treatment planning CT, containing contours of all four bladders of different 
sizes and PTVs. The 3D registration is performed by centring the bladder visible in the 
CBCT image inside the smallest bladder contour encompassing the entire bladder, and 
then the corresponding treatment plan is selected from the library and the treatment is 
delivered. If the lymph node region is treated, then a registration based on bony structures 
is used. No instructions about the fluid intake are given to the patients during the course 
of treatment. A simple description of the treatment workflow is illustrated in Figure 3-1. 
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Figure 3-1. The workflow of the ART for bladder cancer according to the protocol applied at 
HUCH. 
 
Patients and PTV definitions 
 
Altogether 18 patients with muscle-invasive T2–T4a urinary bladder cancer considered 
unfit for cystectomy were included in Studies I–III. No informed consent was obtained 
from the patients, as all these studies were designed to retrospectively evaluate the 
currently applied treatment technique. The patients received ART for bladder cancer at 
HUCH between 2009 and 2014. For 10 patients, Lipiodol contrast agent was injected into 
the bladder wall during cystoscopy to mark the gross tumour volume (GTV) [66,67]. The 
prescribed radiation dose varied according to the treatment volume. In the elective 
treatment phase the patients received ART for the whole bladder with or without lymph 
node irradiation up to 44–50.4 Gy with a fraction size of 1.8 or 2 Gy. CTV-to-PTV 
margins of 10 mm in the anterior and cranial directions and 15 mm in other directions 
were applied for the bladder. An isotropic margin of 7 mm was added around the lymph 
node region, if they were treated. A partial bladder boost treatment of 10–20 Gy was 
delivered using a CTV-to-PTV margin of 10 mm. Three patients received a partial bladder 
treatment of 52.5 Gy/2.5 Gy due to impaired bladder function and several co-morbidities. 
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3.1.2 Modeling inter- and intra-fractional changes in the urinary bladder 
 
For the analysis of time trends in bladder volumes throughout the treatment course, daily 
bladder volumes were contoured in the CBCT images for the patients included in Studies 
I and III. In Study II, intra-fractional volumetric changes were modelled using the bladder 
contours in the successive planning CT images. For these patients, an additional post-
treatment CBCT image was acquired at least on a weekly basis to enable evaluation of 
intra-fractional bladder filling rate. 
 
To estimate the changes of bladder size, a simple ellipsoidal model was applied, using 
the maximal dimensions of bladder in the cranial-caudal (CC, z), anterior-posterior (AP, 
y) and left-right (LR, x) directions, measured from the planning CT scans. The anatomical 
points of origin, relative to which the measurements were performed, were the most 
caudal point in the empty bladder wall (CC direction), the most posterior point in the 
empty bladder wall (AP direction) and the midline of symphysis (LR direction). In the 
ellipsoidal model the bladder volume V was calculated as 
 
? ? ??? ?
????? ? ?????
? ?
???? ? ?????
? ?
????? ? ??????
? ??????????????????????????????????????????????????????????? 
 
where the dimensions z, y and x were measured relative to the anatomical origin. 
To investigate the maximum displacements of the bladder wall during a typical treatment 
fraction of 15 minutes, an assumption was made that all bladder growth is manifested 
only in one dimension, while the other two orthogonal dimensions remain constant. A 
theoretical limit for the maximum change ∆z (or x, y) in the direction of dimension 
growth, caused by the volume change ∆V, can be formulated by differentiating Eq. (1) 
partially with respect to z, while x and y are constant: 
    
??
?? ?
??
? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
Dividing Eq. (2) by V and substituting ? ? ??? ??? gives the rate of the change in bladder 
dimension as a function of volume, 
 
??
?? ?
?
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
which shows that as the volume V increases, the rate of the change of bladder size 
decreases. Alternatively, if the bladder expansion is assumed to be isotropic in all 
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directions (Δz≈Δx≈Δz), the wall displacement is 1/3 of the maximum change given by Eq. 
(3), 
    
??
?? ?
?
?
?
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
The elliptical bladder model and the worst case scenario of intra-fractional bladder 
dimension growth were compared with the actual bladder volume and changes in bladder 
wall extreme positions in planning CT scans in Study II.  
 
3.1.3 Evaluation of normal tissue irradiation and target coverage in ART of urinary 
bladder cancer 
 
In Studies I and III, the benefits of ART strategy for urinary bladder cancer were 
evaluated. For this purpose, bladder and IC contours were segmented in the daily CBCT 
images in Study I. Dose to the IC and dose coverage in the bladder were estimated for the 
ART technique, as compared to the conventional non-ART protocol. Daily IC and bladder 
contours were copied from CBCT images into treatment planning CT images, by applying 
the online image registration of each treatment fraction. Three different dose-volume 
histogram (DVH) curves were calculated for each of the IC volumes using the treatment 
planning CT images. One DVH was calculated using the daily ART plan, and the other 
two DVHs from the non-ART plans using both isotropic and anisotropic CTV-to-PTV 
margins. The total cumulative DVHs for the IC volumes were calculated from the daily 
cumulative DVHs with the numerical computing software Matlab version 7.8 
(MathWorks Inc., Natick, MA, USA), by summing up the absolute doses in bins of 5 cm3 
absolute volume. This direct summation of DVHs produces the “worst case” scenario, 
where the same IC element is constantly at the point of the highest dose. Additionally, 
dose coverage in the bladder was evaluated by recording the minimum doses in the 
bladder for each treatment fraction. 
 
Comparison of two adaptive strategies 
 
In Study III, the strategy of plan library creation applied at HUCH (so-called RepeatCT) 
was compared to a different strategy (so-called RepeatCBCT), which was clinically 
applied at AUH. In the RepeatCBCT method one planning CT with an empty bladder and 
four CBCT images acquired during the first week of treatment were contoured, and the 
bladder contours were combined using Boolean operators to form two adaptive composite 
PTVs. In addition, a non-adaptive PTV was generated by applying generous, population-
 
 
 
 
MATERIALS AND METHODS 
13 
 
based margins around the empty bladder in the planning CT, resulting in a library of three 
different treatment plans. The investigated workflows were slightly modified from the 
original, clinically applied workflows by applying identical image registration procedure 
and CTV-to-PTV margins for both methods, hence enabling a straightforward 
comparison between two methods of generating adaptive PTVs. The margins used in the 
creation of different PTVs can be found in Study III. 
 
3.2 Modeling of salivary gland function for risk-adapted RT of head and 
neck cancers 
 
In Study IV, a model for predicting the loss of salivary gland function after RT for head 
and neck cancers was developed and evaluated. The clinical aim was to provide a tool for 
treatment planning on an individual patient level, for guiding the decision of which 
salivary glands should be spared and to what extent, based on the predicted risk of salivary 
flow degradation. 
 
Patients and measurements 
 
The study population consisted of 70 head and neck cancer patients who received RT at 
HUCH during the years of 2006–2008 (50 patients) and 2012–2013 (20 patients). An 
informed consent was obtained from these patients. All the patients were treated 
bilaterally using thermoplastic mask fixation to the total dose of 50–70 Gy (fractional 
dose 2 Gy), by using an IMRT technique with 6 MV photons. Portal imaging was used 
for verifying patient positioning. Six patients were excluded from the salivary flow model 
due to incomplete sets of measurements. 
 
For the salivary flow model, measurements of both the total volume of the produced 
saliva and relative input from each individual salivary gland to the total saliva output were 
required. Direct measurement of total salivary flow and salivary gland scintigraphy were 
performed before RT (70 patients), 6 months after RT (70 patients) and 12 months after 
RT (50 patients). The rate of the saliva production under oral stimulation was measured 
by collecting saliva in a measuring glass for 15 minutes, when patient was chewing a 
piece of paraffin wax. In scintigraphy, the excretion fractions of individual salivary glands 
were quantified by 30-min dynamic imaging with a gamma camera in 30-s time frames 
beginning simultaneously with an intravenous injection of 99mTc-pertechnetate. After the 
first 15 minutes, 10 ml of 25% lemon juice solution was given orally to the patient to 
stimulate the saliva excretion. A typical scintigraphy curve is presented in Figure 3-2. 
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Figure 3-2. The number of detected counts in a dynamic scintigraphy image for the salivary 
gland’s region of interest (ROI) and background ROI. The number of counts before (Cmax) and 
after (Cmin) the lemon juice stimulus are calculated as an average of four successive image frames. 
Each image in the dynamic series is acquired within 30 s, and the stimulus is applied at t = 15 
min. 
 
The detected counts as a function of time were plotted for five regions of interest (ROI), 
one for each major salivary gland and one for the background. Using the number of counts 
inside the salivary gland ROI right before (Cmax) and after (Cmin) the lemon juice stimulus, 
the salivary excretion fraction sEF was calculated separately for all four glands using the 
equation 
 
??? ? ????? ? ???????? ? ???
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
where Cbg is the number of counts in background ROI, normalized to the salivary gland 
ROI area. The relative excretion fraction at time t after RT was calculated by equation 
 
?????? ? ??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? 
  
where sEF(0) is the baseline value measured before RT. 
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3.2.1 Construction of the individual salivary flow model 
 
The salivary flow model used in Study IV was based on the model reported in the previous 
work of Tenhunen et al. [68]. In this model, the relative total salivary flow under 
stimulation was calculated from a weighted sum of the expected relative excretion 
fractions for all functioning major salivary glands. In Study IV, the idea is developed 
further by using the absolute values of saliva flow rate by adding the parameter of pre-
RT saliva flow rate in the model. The required input parameters for the new model are 
summarized in Figure 3-3.  
 
The weighting coefficients for individual glands were derived by assuming that the 
volume of saliva secreted by a single gland in response to the stimulation is directly 
proportional to the count difference in ROI before and after stimulation, ??? ?
????? ? ?????? . Thus, the proportion of single gland saliva output m of the total saliva 
production could be expressed by the equation 
 
?? ?
???
? ????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
where ? ????  is the sum over all functioning major salivary glands. 
 
Figure 3-3. The input parameters needed for the salivary flow model in the prediction of post-RT 
salivary flow rate for an individual patient. 
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The dose-response relationship for rEF was assumed to have the shape of a sigmoidal 
function described by the equation 
 
??? ? ? ?? ? ?????????
?
?
?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
where Dmean is the mean glandular dose, D50 is the dose for a 50% reduction in sEF and k 
represents the steepness of the curve. For further analysis, parameters D50 and k were 
determined by a nonlinear fitting in Matlab software. However, in the construction of the 
salivary flow model previously reported values of D50 and k were applied [68]. 
The total stimulated salivary flow Fcalc(t) at time t after RT was calculated by applying 
Eqs 7 and 8 in the following expression 
 
???????? ? ???????? ???? ? ????????????????????????????????????????????????????????????????????????????????????????
?
 
 
Here Fmeas(0) is the total stimulated saliva flow rate measured before RT, and mi and 
rEF(Dmean,i) are the proportion of single salivary gland i output of the total saliva output 
and the mean dose-response for gland i, respectively. In this model only the saliva 
production of the parotid and the submandibular glands are included, thus ignoring the 
excretion from the sublingual and the minor salivary glands. 
 
3.2.2 Evaluation of patient-specific variation in salivary gland scintigraphy 
 
A great inter-patient variance has been reported for salivary gland function measured at 
HUCH as well as elsewhere [69,70]. In Study IV, the scintigraphy measurement values 
relative to the mean dose-response curve were further investigated to explore the 
possibility of finding indirect evidence of radiobiologic phenomena related to the detected 
variance. 
 
For this purpose, a subgroup of patients was formed, where the Dmean for both parotid 
glands ranged between 10–50 Gy. This was performed to exclude the nearly flat low and 
high dose regions of the dose-response curve, where there is only a minor change in rEF 
as the Dmean is changed. Submandibular glands were excluded as only a few patients had 
Dmean values of both glands less than 50 Gy. Within the dose-restricted subgroup the effect 
of the mean systematic residual patient positioning error to the Dmean of the glands was 
evaluated from portal images based on the re-registration by using bony structures in the 
surroundings of the salivary glands. The Dmean values were then corrected accordingly. 
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Additionally, rEF>1.3 values were excluded to remove outliers, as well as the salivary 
glands which were not functional before the course of RT. The difference ∆rEF for each 
parotid gland i can be calculated using the equation 
 
????? ? ??????? ? ?????????????????????????????????????????????????????????????????????????????????????????????????????????? 
 
where rEFsc,i is the relative excretion fraction measured by scintigraphy and rEF(Dmean,i) 
represents the value of the mean dose-response function at glandular dose Dmean according 
to Eq. 8. 
 
Finally, a patient-specific mean ΔrEF value (ΔrEFmean) was calculated as an average of 
all four major salivary glands, including also the submandibular glands. The patients were 
sorted in ascending order based on the value of ΔrEFmean, and three groups of equal size 
with low, medium and high ΔrEFmean were formed in order to evaluate inter-patient 
variation in rEF. For each of three groups a new D50 value was determined by re-fitting 
the sigmoidal dose-response function having both parotid and submandibular glands 
pooled together and keeping the k parameter constant. 
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4 Results 
 
 
4.1 Managing organ motion/physiological changes in ART of urinary 
bladder cancer 
 
4.1.1 Time trends in urinary bladder volume 
 
Changes in the urinary bladder volume and dimensions were determined at different time 
scales in order to investigate both inter- and intra-fraction patterns of organ motion. 
Patient data in Studies I and III were pooled together to observe the volumetric chances 
in the bladder during the course of treatment. Bladder expansion during the time scale of 
a single treatment fraction was modelled in Study II. 
 
Inter-fractional changes 
 
A substantial variation in the volume of an empty bladder was detected (Figure 4-1) with 
a trend of decreasing bladder volume towards the end of the treatment course. A weekly 
volume average, calculated as the mean value of bladder volumes for 13 patients during 
each week of treatment up to the 5th treatment week, decreased by 4% per treatment week.  
 
 
Figure 4-1. The fluctuation of bladder volume during the first 25 fractions (5 weeks of treatment). 
The colored lines represent the bladder volume determined from the daily CBCT images relative 
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to the empty bladder volume in the planning CT for 13 individual patients. The black boxes are 
the weekly averages of all 13 patients, and the error bars represent the standard deviation 
(±1SD). The regression line represents a linear fit to the daily bladder volumes. 
 
The range of bladder volumes during treatment showed large differences between the 
patients. The extent of bladder volume variations between treatment fractions was highly 
correlated (R=0.87, p=0.0005) with the volume expansion measured during the 45-
minute planning CT sequence (Figure 4-2). 
 
 
Figure 4-2. The patient-specific (N=11) variation of bladder volume (max-min) in daily CBCT 
images during the course of treatment as a function of bladder volume expansion during the 45-
minute treatment planning CT scanning session. 
 
Intra-fractional changes 
 
The observed enlargement of the bladder diameter between successive CT scans in 15-
min intervals varied between the axis of measurement (Table 4-1). The growth was almost 
symmetric in the AP and LR dimensions. The caudal wall of the bladder did not 
practically move at all while the cranial part was responsible for the majority of the 
movement in the CC direction [II]. Considerable variation in the rate of the bladder 
volume increase was observed with a range of 0.5–4.6 ml/min (mean ± SD = 2.1 ± 1.3 
ml/min), despite the aimed controlled conditions for hydration. In addition, a large intra-
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patient variation with no clear temporal pattern for the urine formation during the entire 
45-min scanning procedure of planning CT was detected [II]. 
 
The bladder volume was modelled with an ellipsoidal shape as a function of the true 
bladder volume determined from the planning CT scans from five patients (Figure 4-3 
A). A worst case scenario, where the bladder volume growth was modelled as a mere 
consequence of growth of one dimension, gave an upper limit for the observed 
dimensional changes (Figure 4-3 B). The excretion of urine into the bladder during the 
treatment delivery was mostly slower than during treatment planning CT acquisition 
(Figure 4-4). On two out of the 25 examined treatment fractions the observed bladder 
filling clearly exceeded the average filling rate during planning CT. [II].  
 
Table 4-1. The mean and maximum changes of bladder diameter and standard deviation (SD) 
during 15-minute intervals between the planning CT acquisitions. Four pairs of successive CT 
images were analysed for each of the five patients.  
 
Measurement axis Mean (mm) SD (mm) Max (mm) 
cranial-caudal 3.8 2.9 10.0 
anterior-posterior 3.4 4.2 9.0 
left-right 1.5 2.4 5.0 
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Figure 4-3. A) Comparison between the bladder volume modelled as an ellipsoid and actual 
bladder volume measured in the planning CT scans. B) The changes of the maximum dimensions 
of the bladder measured in cranial-caudal (C-C), anterior-posterior (A-P) and lateral (DX-SIN) 
directions (open symbols). All the observed changes lie under the level of 1.0 cm (dotted line). 
The calculated theoretical limit for the growth in one dimension (one of C-C, A-P or DX-SIN, 
others unchanged) is plotted in solid circles (fit: solid line) and the theoretical growth in three 
dimensions (all of C-C, A-P and DX-SIN) is plotted with solid squares (fit: dashed line) (Eqs. (3) 
and (4)). [II] 
 
 
Figure 4-4. The filling rates of the bladder during five treatment fractions of five patients as 
measured from pre- and post-treatment CBCT images, compared to the bladder volume growth 
during the 15-minute intervals between the successive planning CT scans. The square symbols 
mark the mean values and the bars indicate the measured range of the filling rates. 
 
4.1.2 The benefits of ART for urinary bladder cancer 
 
The volumes of the irradiated normal tissue 
 
The absorbed dose in the IC was considerably lower by using the ART technique as 
compared to the conventional, non-adaptive technique. A reduction of cumulative dose 
in IC was observed for all five patients included in the analysis [I] (Figure 4-5 A). On 
average, the IC volume receiving at least 45 Gy was reduced by 155 cm3, with a maximum 
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reduction of 240 cm3. For one patient the PTVs included pelvic lymph nodes, gaining the 
minimum IC volume sparing of 65 cm3 at 45 Gy. These values include the effect of partial 
bladder volume irradiation, since all the boost PTVs were smaller than the conventional 
PTVs, which were used for the calculation of the comparison DVHs. However, in Figure 
4-5 B an additional mean DVH for IC was determined using only the initial part of the 
treatment excluding the partial bladder boost, similarly showing a large sparing of the IC 
volume throughout the entire dose range [I]. 
 
In Study III, the normal tissue irradiation was also evaluated relative to another plan-
library-based ART technique for bladder cancer. The volume of normal tissue inside the 
high dose region was determined for each treatment fraction as a difference between the 
daily selected PTV volume and the daily bladder volume as observed in CBCT images 
(Figure 4-6). For all ten patients included in the analysis, the RepeatCT method (based 
on a repeated treatment planning CT imaging sequence) produced smaller mean irradiated 
normal tissue volumes than the RepeatCBCT method (based on one treatment planning 
CT image combined with repeated CBCT imaging). The volume difference was 80 cm3 
on average (p<0.001, paired t-test, two-tailed). Both of the ART methods considerably 
reduced the volume of normal tissue inside the irradiated high-dose volume as compared 
to the non-ART method. However, it should be emphasized that in this comparison the 
CTV-to-PTV margins used for the simulation of the non-ART protocol were larger than 
the margins previously used at HUCH, resulting in relatively high irradiated volumes for 
the non-ART method. 
 
Dose coverage in urinary bladder 
 
Dose coverage in bladder was estimated for the first five patients treated using the ART 
technique [I]. The near-minimum dose as described in ICRU 83 report [71] was used in 
this thesis for the evaluation of dose coverage. Defining a geographical miss as 98% of 
the urinary bladder volume receiving less than 95% of the prescribed dose, no statistically 
significant difference was observed in the rate of geographical miss between the adaptive 
and non-adaptive treatments (3 and 4 fractions out of 125, respectively, p=1.000, 
McNemar test). 
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Figure 4-5. Cumulative DVHs for the intestinal cavity (IC) volume, where the dose is presented 
as a percentage of the total prescription dose. A) Two curves are presented for each patient: the 
‘adaptive’ curves are calculated using the daily adaptive treatment plans, and for comparison 
the ‘conventional’ curves are calculated using a single non-adaptive treatment plan with 
isotropic 20 mm PTV margins. B) The mean cumulative DVHs of IC volumes are calculated as 
an average of all five patients. Two different CTV-to-PTV margins (isotropic and anisotropic) 
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are used to form the non-adaptive mean curves (dotted lines). Two adaptive curves are also 
determined (solid lines): one including only the elective part of the treatment (WBI, whole bladder 
irradiation) and one for the entire treatment including the whole bladder irradiation and the 
partial bladder boost (WBI+boost). [I] 
 
Figure 4-6. The mean volumes PTVdaily–CTVdaily (cm3), averaged across all 30 treatment fractions, 
for the two compared ART methods (repeatCT and repeatCBCT) and a non-ART method. These 
volumes represent the mean volume of normal tissue inside PTV. The error bars indicate the 
volume range. The figure is modified from Study III. 
 
4.2 Predicting salivary gland function in risk-adapted RT of head and neck 
cancers 
 
4.2.1 Individual salivary flow model 
 
The post-RT rates of the absolute excreted saliva volume under stimulation were 
calculated using Eq. (9) with the sigmoidal dose-response function parameters reported 
in [68]. The predicted and measured values are presented in Figure 4-7 for 46 patients 
with a complete set of scintigraphy and salivary flow measurements at the time points of 
6 and 12 months after RT. A significant linear correlation was found between the 
modelled and the directly measured salivary flow rates both six and twelve months after 
RT. The mean prediction errors for the model were 0.45 and 0.36 ml/min for the predicted 
salivary flow 6 and 12 months after RT, respectively.  
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Figure 4-7. A significant linear correlation was seen between the modelled absolute salivary flow 
(Fcalc) and the measured values of salivary flow (Fmeas) both 6 and 12 months after RT. 
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4.2.2 Patient-specific variation in salivary gland scintigraphy 
 
To further investigate the differences in patients’ post-RT salivary function, ∆rEF values, 
defined as the difference between the rEF value measured by scintigraphy and the 
corresponding population mean rEF value at the same glandular dose, were defined for 
the parotid glands. In the pairwise comparison of the left and right parotid glands, the 
∆rEF values were linearly correlated both 6 and 12 months after RT (R=0.53, p=0.0006 
and R=0.79, p<0.0001, respectively). Additionally, the ∆rEF values were compared for 
the same parotid gland at two different times of measurement (6 and 12 months after RT), 
showing a linear correlation (R=0.53, p<0.0001). In Figure 4-8, the sEF values measured 
by scintigraphy are presented for the major salivary glands 6 and 12 months after RT. 
The repeatability of the scintigraphic excretion fraction measurement is moderate, as a 
good positive correlation was shown between the two measurements at different times. 
Minor recovery of the salivary gland function was detected between the period of 6 and 
12 months after RT (from 0.22 to 0.25 on average, p=0.0008, two-tailed paired t-test). 
 
 
Figure 4-8. A positive linear correlation (R=0.82, p<0.0001) was established between the 
scintigraphy sEF measurements at 6 and 12 months after RT, reflecting a moderate stability of 
the measurement technique. Mean sEF values were 0.22 and 0.25 at 6 and 12 months after RT, 
respectively, showing a mild recovery of the salivary gland function (p=0.0008, pairwise t-test, 
two-tailed). 
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For some patients the measured post-RT rEF values of the both parotid glands (left and 
right) were clearly either above or below the mean dose-response curve. This behaviour 
was present at both times of measurement (6 and 12 months after RT). Hence, it was 
concluded that the systematic differences found in ΔrEF values between the patients were 
not generated by transient instabilities in the scintigraphy measurement technique. From 
these results it was deduced that there can be some biological factor, such as intrinsic 
radiosensitivity, that affects the post-RT scintigraphy results. 
 
In further evaluation of inter-patient differences in post-RT salivary gland function, 
ΔrEFmean calculated as an average of all the functioning major salivary glands was used. 
The patients were divided into three groups of equal size with low, medium and high 
ΔrEFmean, with an average ΔrEFmean value of -0.25, 0.02 and 0.24, respectively. The re-
fitting of a sigmoidal dose-response function resulted in D50 values of 23, 36 and 42 Gy 
for the low, medium and high ΔrEFmean groups, respectively (Figure 4-9). These values 
correspond to the absorbed doses causing a fifty-percent degradation of sEF in the three 
groups. This gives an idea of the range of variation in an individual patient’s response to 
RT.  
 
Figure 4-9. Relative excretion fraction (rEF) for individual salivary glands with the patients 
divided into three groups: low ΔrEFmean (open circles), medium ΔrEFmean (filled squares) and high 
ΔrEFmean (asterisks). A sigmoidal dose-response function is plotted for the three separate groups 
yielding D50 values of 23, 36 and 42 Gy for the respective groups. 
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5 Discussion 
 
 
In the following the results presented in this thesis are discussed and critically evaluated, 
taking the limitations of the performed measurements and analysis into account. In 
addition, aspects for future development and possible applications are discussed. 
 
5.1 Changes of bladder dimensions between and during RT treatment 
fractions  
 
Even though the patients were instructed to empty their bladder before each treatment 
fraction, considerable variation in the bladder volume was present during the course of 
RT. The difficulty of maintaining constant bladder volume throughout RT has been 
widely recognised in the literature over time [72-76]. One appealing solution in the 
attempt of standardizing the bladder volume for the entire course of RT would be 
catheterization. However, the use of indwelling catheters has been associated with 
infections of the urinary tract [77]. In this study, some patients showed clearly more 
fluctuation in the bladder volume than the others. Also, the measured bladder volume 
expansion during the acquisition of four planning CTs correlated with the range of 
bladder volumes during treatment. In future, this information could be used to limit the 
number of treatment plans in the library for those patients whose bladder showed only 
modest expansion between planning CTs.  
 
As RT is usually the choice of treatment for patients unfit for cystectomy, in this 
population the patients often have several co-morbidities that may influence the patient’s 
ability to void. For example, one patient showing the largest variation in bladder size was 
disabled, and voiding the bladder exactly at the right moment may have been difficult. 
Some of the detected large volumes were also related to the intensive hydration during 
chemotherapy. Nevertheless, the fact that for most of the patients the bladder volumes 
could not be controlled by merely giving instructions about voiding, demonstrates the 
need for an adaptive strategy for this particular tumour site. 
 
The intra-fractional expansion of the bladder was investigated in this research by 
observing the changes in the bladder dimensions between successive planning CTs. This 
yielded further information about the dimensional changes related to different bladder 
volumes from an empty to a full bladder. In addition, it was verified that the bladder 
filling rate was generally lower in the treatment than during planning CT acquisition. The 
 
 
 
 
DISCUSSION 
30 
 
values in Table 4-1 give the measured maximal changes of the bladder diameter during 
the 15-minute intervals. In the sample of five patients, the dimensional changes in LR and 
AP directions were found to be mostly symmetric. Hence, using a soft tissue matching 
protocol in the treatment, the 10 mm maximum expansion can be divided in half (5 mm) 
to give the intra-fractional margin in the LR and AP directions. In the treatment setup 
applied at HUCH, a 10 mm margin should be added in the cranial direction to account 
for intra-fractional filling and bladder deformation, and in the caudal direction the margin 
can be less than 3 mm. These margins would cover all of the detected intra-fractional 
changes in the treatment set-up applied at HUCH, and they are only adequate for the 
maximum time of 15 minutes elapsed from the acquisition of CBCT to the end of 
irradiation. However, as the number of patients included in the study is very small, any 
general recommendations about the intra-fractional margins applied for bladder ART 
cannot be given. Instead, the aim was to verify that the CTV-to-PTV margins used in the 
bladder ART protocol at HUCH were adequate. According to this study the margins used 
were generous and they could even be reduced in the lateral and posterior directions. 
Other studies have addressed intra-fractional expansion of the bladder using MR 
[73,78,79] or CT imaging [76,80]. Intra-fractional margins of 5-6 mm have been 
suggested in the literature [79,80]. Nevertheless, the magnitude of these margins depends 
on the conformity of the applied treatment technique (3D conformal, IMRT or VMAT). 
 
5.2 ART workflow for urinary bladder cancer implemented at HUCH 
 
The first bladder cancer patients were treated at HUCH in 2009 using the described ART 
protocol. Thus, the HUCH Cancer Center was among the first clinics in the world to 
implement a plan-library-based ART for urinary bladder cancer. The applied workflow 
has evolved during the years, including the planning CT procedure, the choice of 
treatment technique, the online matching procedure and the plan selection criteria. At 
first, several planning CT intervals were tested, starting from a 30-minute interval 
between the successive scans. However, quite soon this was gradually reduced to 15 
minutes, which was found to be optimal both in terms of the patients’ ability to hold the 
urine during bladder filling and both personnel and time resources of the department. At 
the same time, the amount of water intake right before the first CT scan was increased 
from 2 dl to 8 dl. The treatment technique was changed from IMRT to VMAT in 2011, 
enabling faster treatment delivery. At very early stage of implemented ART, the matching 
of daily CBCT to planning CT image was performed using bony structures. Nevertheless, 
rather soon it became obvious that occasionally some manual adjustments were required 
during the matching procedure due to variable rectum filling leading to bladder shifting 
or deformation. Finally, it was decided to apply full soft tissue matching to compensate 
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for changes in rectum filling. For the first five patients treated with ART, the criterion for 
the plan selection was different than for the subsequent patients. For these patients, the 
smallest PTV encompassing the entire bladder with at least a 3-mm margin was selected. 
This intra-fractional margin of 3 mm was derived from the literature as an average 
movement of the bladder wall between pre- and post-RT CBCT [81]. However, the 
adequacy of this intra-fractional margin was later questioned, and full CTV-to-PTV 
margins were exploited by selecting the plan using the CTV contour which was the closest 
match to the daily bladder volume. 
 
According to this study, regardless of the CTV-to-PTV margin reduction from 20 mm 
isotropic to 10–15 mm anisotropic margin, the dose coverage of the urinary bladder was 
not compromised when changing from the non-adaptive treatment technique to ART. The 
absorbed dose to the IC was evaluated by direct summation of single fraction DVHs based 
on daily contours of bowel cavity. This procedure yields a rough approximation of the 
cumulative dose in a worst case scenario where the highest dose always affects the same 
part of the bowel cavity. Nowadays, there are deformable registration algorithms 
available in commercial software, enabling cumulative dose tracking for individual 
voxels of interest [82]. However, due to the constant peristaltic motion and deformation 
of the small bowel, tracking the dose for the intestines would be challenging at least, if 
not impossible. Several studies have addressed the topic of normal tissue sparing in 
bladder ART [24,35,38,40,83]. Yet, only a few studies have based their evaluation on 
daily DVH curves for the OARs as seen in the CBCTs [40,83], and Study I was the first 
to report clinical results using this approach. In the presented research a large reduction 
in the irradiated IC volume was seen, which was similar to the results obtained in other 
studies [38,40]. 
 
A clinically interesting comparison was made between the ART protocol applied at 
HUCH (RepeatCT) and another plan-library-based protocol that had been used at AUH 
(RepeatCBCT) [84]. The aim of this study was to determine whether one of the methods 
of creating the adaptive PTVs was superior in terms of normal tissue sparing and range 
of different PTV volumes. To manage this simulation study, some alterations in the 
original workflows had to be done, and hence the clinically used methods could not be 
compared directly. A significant difference was found in the volume of the irradiated 
normal tissue, in favour of the RepeatCT method. However, for some patients the 
repeated planning CT sequence failed to predict the bladder shape during the course of 
treatment, causing even the largest PTV to be inadequate to cover the entire bladder for 
a few fractions. For these few patients the RepeatCBCT method yielded a more suitable 
selection of different PTV shapes. If the shape of the bladder is radically different from 
 
 
 
 
DISCUSSION 
32 
 
the planning CTs during the first treatment fractions, it could be recommended that two 
additional adaptive PTVs should be added in the RepeatCT library using the 
RepeatCBCT method for PTV definition. At HUCH the RepeatCT method has been 
found to be more appealing, as it leaves more time for performing the contouring and 
treatment planning, and provides better image quality for contouring. In addition, as some 
of the elderly patients receive moderately hypofractionated RT, a protocol starting the 
ART right from the first treatment fraction can be beneficial. 
 
As a non-standard method, plan-library-based ART requires special attention at all stages 
of the RT to avoid errors. At the moment, all commercial treatment verification systems 
do not adequately support the use of several alternative treatment plans. Therefore, 
additional care is required from the therapists to pick and deliver the correct treatment 
plan from the verification system. The patients included in this research have been treated 
partly by using the Varian Clinac iX linac connected to ARIA verification system, and 
partly by using the Elekta Axesse linac together with the Mosaiq verification system. It 
is essential, that in the near future the commercial software manufacturers would find a 
better way to support the use of treatment plan libraries. 
 
Plan-library-based ART may be seen as a transition phase towards daily online re-
optimization of the treatment plans based on pre-fraction imaging. However, 
implementation of such online ART strategies requires a lot of effort before they will be 
ready to be introduced to clinical routine. Even if all the technical challenges, such as 
rapid and reliable deformable registration, fast online re-optimization, dose accumulation 
and quality assurance (QA) could be resolved, the question of who takes responsibility 
for the daily contours and the treatment plans still remains. A plan-library-based approach 
for the ART of urinary bladder cancer is a robust method that requires relatively small 
effort for its implementation. An additional advance of this method is that QA for the 
treatment plans can be performed before the initiation of the treatment course. Therefore, 
this approach can be expected to remain as the state-of-the-art method also in the future. 
The method is applicable for other tumour sites as well [26,85,86], and the future plan at 
HUCH is to implement a similar approach to cervical cancer. 
 
5.3 Prediction of salivary flow after RT of head and neck region 
 
A step towards risk-adaptive RT for head and neck cancers was taken by constructing a 
predictive model for post-RT saliva excretion. A significant correlation was established 
between the predicted and measured values of salivary flow. The idea behind this model 
was to determine the contribution of each individual salivary gland to the total saliva 
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output by a pre-RT scintigraphy measurement. These proportional values were then 
scaled using the estimated population-based dose-response functions. This approach 
differs from many other published salivary function models [87-91]. In the generally used 
normal tissue complication probability models, a single endpoint is selected to represent 
the radiation-induced complication [60,92]. For example, in a model for salivary function, 
a 75% loss of saliva excretion could be considered as a complication. The advantage of 
our model is that it describes salivary function in a continuous manner, and no threshold 
value needs to be introduced to define the presence of a complication. 
 
However, the predicted values of saliva excretion did not have a perfect correspondence 
with the measured ones. Therefore, also the patient-specific variation in the scintigraphy 
measurements was investigated.  For this purpose, the distances of the rEF values for the 
individual glands from the mean dose-response curves were determined in order to see if 
all four major salivary glands of an individual patient behave similarly. In this analysis, 
a common pattern of reaction of individual glands was detected. Hence, there may be a 
common factor, such as a patient-specific sensitivity, which may explain the similar 
deviation of separate glands from the mean dose-response curve when compared to each 
other at the same time point, and even at two different time points. It is unlikely that some 
other unknown random factor, such as the consistence of the stimulus, the daily variation 
of the patient’s response to the stimulus or any variation related to the scintigraphic 
analysis, would cause a similar effect in both bilateral glands at two different times of 
measurement. Hence, this result can be considered as indirect evidence for some 
mechanism of patient-specific sensitivity that each gland follows. 
 
Three different patient groups were artificially formed based on the use of ΔrEFmean value 
calculated for all four major salivary glands.  These groups consisted of patients having 
high, medium and low dose-response as compared to the population average. The purpose 
of this analysis was to give an idea of the variation in data and D50 doses due to possible 
patient-specific sensitivity to radiation. The D50 values given by the analysis were 23, 36 
and 42 Gy for the different groups, respectively. However, these data include the overall 
uncertainty of the method, and the contribution of radiosensitivity could not be 
exclusively extracted. As an additional experiment, absolute salivary flow was re-
calculated using the separate D50 values for the three patient groups. This resulted in a 
clearly better agreement between the calculated and measured values for the groups with 
low and high dose-response. This supports the idea that if we had a-priori knowledge 
about individual radiosensitivity of the patients, and it could be quantified and taken into 
account in the predictive model, the accuracy of the model could possibly be improved. 
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The limitations of the performed analysis include the large uncertainty of the scintigraphic 
measurements. In a study by Firat et al. [93], applying a similar technique to ours, a SD 
of 0.09-0.14 in sEF was observed in different age groups of normal subjects for both 
parotid and submandibular glands. A SD of 0.14 in sEF corresponds to a SD of 0.2 for 
rEF, which is calculated as a ratio of two sEFs. The true SD is likely to be smaller for the 
relative values, as the variance in sEF also includes possible inter-patient variations in the 
reaction to the stimuli, which is eliminated in rEF. Hence, 0.2 can be estimated to give an 
absolute upper limit for the variation in rEF. In our scintigraphy data, the standard error 
for the fit of the sigmoidal dose-response curve was 0.42 for the parotid glands. This 
suggests that there remains a large component of variation, which cannot be explained by 
the measurement technique, and this could be partly due to radiosensitivity. The effect of 
smoking to the dose-response was not investigated in this study. 
 
In the pairwise analysis of parotid glands, the effect of mean systematic residual patient 
positioning error to the Dmean of the glands was evaluated from portal images using the 
bony structures close to the parotid glands for matching, and the Dmean values were 
corrected accordingly. In dose accumulation studies, even quite large discrepancies 
between the planned and actually delivered Dmean doses have been reported. However, 
when the calculated doses are compared to the delivered ones rather complex positional 
changes, such as rotations of the neck or head, may have a large impact on the dose 
delivered to the glands, if the patient positioning has been done according to the cervical 
vertebrae. In a dose accumulation study by Hunter et al. [70], the median delivered mean 
parotid dose increased by 0.9 Gy, which is in accordance with other similar studies. The 
complex setup deviations were identified as a major cause for the large dose 
discrepancies, as the large dose differences were already present in the first treatment 
fraction. In our analysis, the mean effect of the setup deviations in parotid Dmean was 
estimated. Hence, possible errors in the Dmean values in the present analysis are mainly 
due to the possible shrinkage and shifting of the glands. In the literature, this has been 
given a mean value of 3 mm towards the midline, which in our patient data corresponds 
to a dose increase of 1.2 Gy [69,94]. As the slope of the dose-response curve for parotid 
glands was not very steep, an error of this magnitude in Dmean would not have a large 
effect in ΔrEF. Also, as shrinkage and shifting of the parotid glands would increase the 
Dmean, it cannot explain the large positive ΔrEF values. Interestingly, in the study by 
Hunter et al. [70], the use of the actual delivered doses did not decrease the large 
dispersion of the dose-effect data points in salivary output measurements. This may be 
true for scintigraphic measurements as well, and it provides support for the idea of 
radiosensitivity being one of the factors explaining the variation in post-RT saliva 
secretion. 
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Encouraged by this research, systematic pre-RT salivary gland scintigraphy was recently 
initiated for all head and neck cancer patients at HUCH. The aim is to find out which 
salivary glands have the largest effect on the total saliva output. Then, if possible, the 
treatment plan could be adjusted so that the post-RT saliva excretion can be maximized 
without compromising the target dosage. 
 
At HUCH, there is an ongoing research project, where the pre-RT salivary gland function 
has been measured both using scintigraphy and diffusion-weighted MRI. It would be 
optimal to find a quantitative indicator of salivary function on MRI, which could be used 
for modelling of the post-RT salivary function. Thus, the salivary gland scintigraphy 
could be replaced with a non-irradiative procedure. The MRI also provides volumetric 
image with high spatial resolution, enabling separation of different functional volumes 
inside the salivary gland. A plan for the near future is to investigate the possible regional 
differences within the glands and how they could affect the dose-response of the salivary 
glands, with the aim of increasing the potential for risk-adapted RT in the head and neck 
region. 
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6 Conclusions 
 
 
In the present thesis, two methods for incorporating individual physiological changes in 
RT treatment planning were developed. Both suggested methods aimed at reducing dose 
to the normal tissues. The first method, ART for urinary bladder cancer, was implemented 
and found feasible for routine clinical use. The second method was designed to aid 
treatment planning for head and neck cancers. The thesis reached its aims with the 
following main conclusions: 
 
1) The inter- and intra-fractional changes in the urinary bladder were quantified in 
order to take them into account in ART for urinary bladder cancer. Considerable 
variation was detected in the volumes of residual urine in the voided bladders, 
which pointed out the need for an adaptive treatment strategy. An investigation of 
the intra-fractional variations in the urinary bladders confirmed the adequacy of 
the applied CTV-to-PTV margin, 
 
2) A plan-library-based workflow of ART for urinary bladder cancer was clinically 
implemented at HUCH. It was shown to reduce the absorbed dose to the IC, while 
the dose coverage in the bladder remained at the same level as in the conventional, 
non-adaptive method. The method applied at HUCH was compared with another 
clinically implemented plan-library-based method, resulting in a significant 
difference in the volumes of irradiated normal tissue, in favour of the HUCH 
method, and 
 
3) A clinically feasible method of predicting post-RT saliva excretion was developed 
by using the pre-RT measurements of salivary gland function and the dose 
information from treatment plans. A good correlation between the modelled and 
measured values of salivary flow was established. A partly unexplained variation 
was present in the post-RT excretion fraction values measured with scintigraphy. 
This was considered as indirect evidence of the possibility of patients’ intrinsic 
individual radiosensitivity having an effect on post-RT salivary function.   
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